Circulating Omentin-1 as a Biomarker at the Intersection of Postmenopausal Breast Cancer Occurrence and Cardiometabolic Risk: An Observational Cross-Sectional Study

Gerasimos Socrates Christodoulatos; Georgios Antonakos; Irene Karampela; Sotiria Psallida; Theodora Stratigou; Natalia Vallianou; Antigoni Lekka; Ioanna Marinou; Evaggelos Vogiatzakis; Styliani Kokoris; Athanasios G. Papavassiliou; Maria Dalamaga

doi:10.3390/biom11111609

Biomolecules (Oct 2021)

Circulating Omentin-1 as a Biomarker at the Intersection of Postmenopausal Breast Cancer Occurrence and Cardiometabolic Risk: An Observational Cross-Sectional Study

Gerasimos Socrates Christodoulatos,
Georgios Antonakos,
Irene Karampela,
Sotiria Psallida,
Theodora Stratigou,
Natalia Vallianou,
Antigoni Lekka,
Ioanna Marinou,
Evaggelos Vogiatzakis,
Styliani Kokoris,
Athanasios G. Papavassiliou,
Maria Dalamaga

Affiliations

Gerasimos Socrates Christodoulatos: Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527 Athens, Greece
Georgios Antonakos: Laboratory of Clinical Biochemistry & Laboratory of Hematology and Blood Bank Unit, Medical School, National and Kapodistrian University of Athens, Attikon General University Hospital, 1 Rimini Street, Chaidari, 12462 Athens, Greece
Irene Karampela: 2nd Department of Critical Care, Medical School, University of Athens, Attikon General University Hospital, 1 Rimini Street, Chaidari, 12462 Athens, Greece
Sotiria Psallida: Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527 Athens, Greece
Theodora Stratigou: Department of Internal Medicine and Endocrinology, Evaggelismos General Hospital, 45-47 Ypsilantou Street, 10676 Athens, Greece
Natalia Vallianou: Department of Internal Medicine and Endocrinology, Evaggelismos General Hospital, 45-47 Ypsilantou Street, 10676 Athens, Greece
Antigoni Lekka: Laboratory Department, NIMTS-Army Share Fund General Hospital, 12 Monis Petraki and Vasilissis Sofias Avenue, 11528 Athens, Greece
Ioanna Marinou: Laboratory Department, Sotiria Athens General Hospital, 152 Mesogeion Avenue, 11527 Athens, Greece
Evaggelos Vogiatzakis: Laboratory Department, Sotiria Athens General Hospital, 152 Mesogeion Avenue, 11527 Athens, Greece
Styliani Kokoris: Laboratory of Clinical Biochemistry & Laboratory of Hematology and Blood Bank Unit, Medical School, National and Kapodistrian University of Athens, Attikon General University Hospital, 1 Rimini Street, Chaidari, 12462 Athens, Greece
Athanasios G. Papavassiliou: Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527 Athens, Greece
Maria Dalamaga: Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527 Athens, Greece

DOI: https://doi.org/10.3390/biom11111609
Journal volume & issue: Vol. 11, no. 11
p. 1609

Abstract

Read online

Aberrant circulating omentin-1, which is an anti-inflammatory and pro-apoptotic adipokine, has been reported in various solid tumors. Therefore, we investigated whether or not circulating omentin-1 could be associated with postmenopausal BC (PBC) and could be used as a potential diagnostic and clinical tool taking into consideration clinicopathologic features, tumor markers, as well as anthropometric, metabolic, and inflammatory parameters. Serum omentin-1, tumor markers (CA15-3 and CEA); metabolic (insulin, glucose, HOMA index, and serum lipids), anthropometric (BMI, waist circumference, and fat mass), and inflammatory (TNF-α, IL-6, hsCRP) parameters; classic adipokines (leptin and adiponectin); the Mediterranean diet (MedDiet) score; and cardiovascular (CVD) risk were determined in 103 postmenopausal women with pathologically confirmed incident invasive BC, 103 controls matched on age, 51 patients with benign breast lesions (BBL), and 50 obese postmenopausal women of similar age. The mean serum omentin-1 was significantly lower in cases than in controls and patients with BBL (p p < 0.05). In all study participants, omentin-1 was negatively correlated with CVD risk and positively correlated with MedDiet score. Lower circulating omentin-1 was independently associated with PBC occurrence above and beyond known risk factors. According to the ROC curve analysis, the overall diagnostic performance of omentin-1 (0.84, 95% CI 0.79–0.89) is similar to CA15-3. Circulating omentin-1 may be a biomarker at the intersection of PBC and cardiometabolic risk in postmenopausal women, and could be modulated by the adoption of a MedDiet. Further mechanistic and large multicentric prospective and longitudinal studies are required to elucidate the ontological role of omentin-1 in BC and CVD risks, as well as its diagnostic and prognostic ability and its therapeutic potential.

Published in Biomolecules

ISSN: 2218-273X (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Microbiology
Website: https://www.mdpi.com/journal/biomolecules

About the journal

Abstract

Keywords